文献速递肺外科

非小细胞肺癌患者化疗联合纳武利尤单抗及化疗联合纳武利尤单抗与伊匹木单抗后的手术结局

Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-10-08

研究基于NEOSTAR试验序贯平台队列,44例可切除IB(≥4 cm)至IIIA期非小细胞肺癌患者分别接受纳武利尤单抗+化疗(22例)或伊匹木单抗+纳武利尤单抗+化疗(22例),评估手术可行性与围术期结局。两组分别有100%和90.9%完成手术切除,R0率分别为90.9%和95%,≥3级Clavien-Dindo并发症分别为18.2%和20%,约半数切除(22/42,52.3%)被认为比标准肺叶切除更具挑战性。

要点

  • 纳武利尤单抗+化疗组22例全部手术,R0 20例(90.9%),≥3级并发症4例(18.2%)。
  • 伊匹木单抗+纳武利尤单抗+化疗组20/22例手术,R0 19例(95%),≥3级并发症4例(20%)。
  • 全部42例手术中22例(52.3%)被认为比标准肺叶切除更具挑战性。

核心结论

  • 新辅助化疗联合纳武利尤单抗(联合或不联合伊匹木单抗)后手术切除可行且安全,R0率较高。

研究设计与样本

  • NEOSTAR试验序贯平台队列,共44例IB(≥4 cm)至IIIA期非小细胞肺癌患者,22例接受纳武利尤单抗+化疗,22例接受伊匹木单抗+纳武利尤单抗+化疗;以30天并发症率评估手术安全性,通过手术记录和外科医生叙述评估手术复杂性和操作方式。

主要发现

  • 纳武利尤单抗+化疗组22/22例(100%)手术切除:R0 20例(90.9%),肺叶切除17例(77.3%)、楔形切除1例、肺段切除2例、全肺切除2例;21/22例(95%)经开胸完成;13/22例(59.1%)评为挑战性切除;4/22例(18.2%)发生≥3级Clavien-Dindo并发症。
  • 伊匹木单抗+纳武利尤单抗+化疗组20/22例(90.9%)手术切除:R0 19例(95%),肺叶切除18例(90%)、全肺切除1例、肺段切除1例;16/20例(80%)经开胸、3/20例(15%)经机器人、1/20例(5%)经胸腔镜完成;9/20例(45%)视为挑战性切除;4/20例(20%)发生≥3级Clavien-Dindo并发症。
  • 总体上约半数病例(22/42,52.3%)被认为比标准肺叶切除更具挑战性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Chemotherapy plus nivolumab is the standard of care neoadjuvant treatment for patients with resectable stage IB to IIIA non-small cell lung cancer. The influence of dual checkpoint blockade with chemotherapy on surgical outcomes remains unknown. We aimed to determine operative complexity and perioperative outcomes associated with neoadjuvant chemotherapy and nivolumab with or without ipilimumab. METHODS: A total of 44 patients with stage IB (≥4 cm) to IIIA non-small cell lung cancer were treated on sequential platform arms of the NEOSTAR trial. A total of 22 patients were treated with nivolumab + chemotherapy, and 22 patients were treated with ipilimumab + nivolumab + chemotherapy. The safety of surgical resection after neoadjuvant therapy was estimated using 30-day complication rates. Operative reports and surgeons' narratives were evaluated to determine procedural complexity and operative conduct. RESULTS: All 22 of 22 patients (100%) treated with nivolumab + chemotherapy underwent surgical resection: 20 R0 (90.9%), 17 (77.3%) lobectomies, 1 wedge resection, 2 segmentectomies, and 2 pneumonectomies. The majority, 21 of 22 (95%), were performed by thoracotomy. A total of 13 of 22 (59.1%) were rated as challenging resections. A total of 4 of 22 patients (18.2%) experienced grade 3 or greater Clavien-Dindo complication. A total of 20 of 22 patients (90.9%) treated with ipilimumab + nivolumab + chemotherapy underwent surgical resection: 19 R0 (95%), 18 (90%) lobectomies, 1 pneumonectomy, and 1 segmentectomy. A total of 16 of 20 (80%) resections were performed via thoracotomy, 3 of 20 (15%) via robotics, and 1 of 20 (5%) via thoracoscopy. A total of 9 of 20 (45%) resections were considered challenging. A total of 4 of 20 patients (20%) experienced grade 3 or greater Clavien-Dindo complication. CONCLUSIONS: Surgical resections are feasible and safe, with high rates of R0 after neoadjuvant chemotherapy and nivolumab with or without ipilimumab. Overall, approximately half of cases (22/42, 52.3%) were considered to be more challenging than a standard lobectomy.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Feldman H, Sepesi B, Leung CH, et al. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023. PMID: 37816395. doi:10.1016/j.jtcvs.2023.09.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。